Ogihara T, Yoshinaga K, Kamahara Y, Ikeda M, Goto Y, Arakawa K, Iimura I, Ishii M, Kokubu T, Takeda T
Department of Geriatric Medicine, Osaka University Medical School, Japan.
J Cardiovasc Pharmacol. 1991;18 Suppl 4:S69-72.
In an open clinical study, the efficacy and safety of carvedilol was investigated in 26 severely hypertensive patients controlled inadequately on a diuretic [diastolic blood pressure (DBP) greater than 120 mm Hg at first visit and greater than 110 mm Hg following more than 1 week administration of a diuretic]. Following diuretic treatment all patients were initially administered 5 mg of carvedilol once daily. The dose was gradually increased to 10 mg and 20 mg until DBP was reduced below 100 mm Hg or until it was reduced by at least 10 mm Hg. Antihypertensive activity of carvedilol (5 mg) was sufficient in only three cases, but after 4 weeks (inpatients) or 8 weeks (outpatients) administration of carvedilol (10 mg or 20 mg), DBP/systolic blood pressure was significantly reduced from 176 +/- 6/117 +/- 3 to 145 +/- 3/94 +/- 2 mm Hg (p less than 0.001) in all patients. Overall, a sufficient antihypertensive effect was observed in 80% of the patients. Heart rate was significantly decreased from 76 +/- 2 to 67 +/- 2 beats/min, but no patient experienced bradycardia. Carvedilol was generally well tolerated. These findings suggest that 10-20 mg of carvedilol once daily, in combination with a diuretic, is an effective and safe treatment for patients with severe hypertension.
在一项开放性临床研究中,对26例使用利尿剂后血压控制不佳的重度高血压患者[首次就诊时舒张压(DBP)大于120 mmHg,使用利尿剂超过1周后大于110 mmHg],研究了卡维地洛的疗效和安全性。在利尿剂治疗后,所有患者最初每天服用一次5 mg卡维地洛。剂量逐渐增加至10 mg和20 mg,直到DBP降至100 mmHg以下或至少降低10 mmHg。仅3例患者中卡维地洛(5 mg)的降压活性足够,但在服用卡维地洛(10 mg或20 mg)4周(住院患者)或8周(门诊患者)后,所有患者的DBP/收缩压从176±6/117±3显著降至145±3/94±2 mmHg(p<0.001)。总体而言,80%的患者观察到足够的降压效果。心率从76±2显著降至67±2次/分钟,但没有患者出现心动过缓。卡维地洛总体耐受性良好。这些发现表明,对于重度高血压患者,每天一次10 - 20 mg卡维地洛联合利尿剂是一种有效且安全的治疗方法。